ReviewPediatric nephrology (Berlin, Germany)1991
Practical aspects in the use of cyclosporin in paediatric nephrology.
Review in Pediatric nephrology (Berlin, Germany), 1991. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Cyclosporine A vs. methylprednisolone for Henoch-Schönlein nephritis: a randomized trial.Pediatric nephrology (Berlin, Germany) · 2011Trial
- Improved absorption of cyclosporin A from a new microemulsion formulation: implications for dosage and monitoring.Pediatric nephrology (Berlin, Germany) · 1995Trial
- Steroid-resistant, cyclosporine-responsive, relapsing nephrotic syndrome.Pediatric nephrology (Berlin, Germany) · 1995Trial
- Commentary on "Pediatric Idiopathic Steroid-sensitive Nephrotic Syndrome Diagnosis and Therapy - Short version of the updated German Best Practice Guideline (S2e)".Pediatric nephrology (Berlin, Germany) · 2021Article
- Pathogenesis and Management of Acute Kidney Injury in Patients with Nephrotic Syndrome Due to Primary Glomerulopathies.Medicina (Kaunas, Lithuania) · 2019Review
- Cyclosporine-A-induced nephrotoxicity in children with minimal-change nephrotic syndrome: long-term treatment up to 10 years.Pediatric nephrology (Berlin, Germany) · 2008Article
- Cyclophosphamide in steroid-sensitive nephrotic syndrome: outcome and outlook.Pediatric nephrology (Berlin, Germany) · 2003Article
- Cyclosporin A pharmacokinetics in a patient with psoriasis and obesity, presenting with high levels of low-density [correction for destiny] lipoprotein.European journal of clinical pharmacology · 2002Article
- Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children.Bone marrow transplantation · 2000Article
- Pediatric clinical use of the ketoconazole/cyclosporin interaction.Pediatric nephrology (Berlin, Germany) · 1994Article
- The interaction of the calcium channel blockers verapamil and nifedipine with cyclosporin A in pediatric renal transplant patients.Pediatric nephrology (Berlin, Germany) · 1994Article
- Cyclosporine pharmacokinetics in nephrotic and kidney-transplanted children.European journal of clinical pharmacology · 1994Article
- In what order should one introduce cyclophosphamide or chlorambucil, cyclosporine or levamisole in a child with steroid-dependent frequently relapsing nephrotic syndrome?Pediatric nephrology (Berlin, Germany) · 1993Article
- Review
- Paediatric aspects of renal transplantation: experience of a single centre.European journal of pediatrics · 1992Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many factors must be considered for the effective and safe use of cyclosporin A (CsA) in paediatric nephrology. Detailed knowledge of the variable bioavailability, tissue distribution, and metabolism, as well as causes which lead to their alteration are necessary. Factors which affect the activity of the mixed function oxidase system cytochrome P-450 must be considered, i.e. liver dysfunction and many drugs. Precise knowledge of the CsA determination method and the spectrum of metabolites is essential. In children with renal transplants, a body surface area-related dose will better meet the dose requirements than a body weight related-dose. For drug level monitoring whole blood rather than plasma should be used, and the parent drug level should be the main determinant; elevated metabolite levels may be important in suspected nephrotoxicity or liver dysfunction. Pharmacokinetic profiles are necessary to discover absorption problems or increased CsA clearance rates which necessitate shorter dosing intervals. In children with steroid-dependent minimal change nephrotic syndrome, remission without steroids is maintained as long as CsA is given. The appropriate starting dosage is 150 mg/m2 per day; trough level monitoring is mandatory to prevent nephrotoxicity and to confirm adequate immunosuppressive drug levels which should be 80-160 ng/ml (parent drug level). Although the benefit of CsA has been reported in some cases of lupus erythematosus, its use should be restricted to severe cases only until its efficacy and safety has been confirmed in controlled trials.
Indexed as
Identifiers
1911153What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.